First-in-Human, Phase 1, Randomized, Double-Blind, Placebo-Controlled Study of TNX-1500, an Fc-Modified anti-CD154 Monoclonal Antibody, Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Ascending Doses in Healthy Adults

Journal of Clinical Immunology · Published 2026-04-29 · DOI 10.1007/s10875-026-02028-8

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.1007/s10875-026-02028-8

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Related articles